MacLennan A H, Gill T K, Broadbent J L, Taylor A W
Discipline of Obstetrics & Gynaecology, School of Paediatrics and Reproductive Health, The University of Adelaide, The Women's and Children's Hospital, South Australia, Australia.
Climacteric. 2009 Apr;12(2):122-30. doi: 10.1080/13697130802666251.
To describe the prevalence of menopausal hormone therapy (HT) in 2008 and trends over the last 17 years in an Australian population.
Data were obtained from nine representative population face-to-face interview surveys of the South Australian population from 1991 to 2008. The surveys used consistent method and quality control procedures. In 2008, demographic data, HT use and eight dimensions of health, using the SF-36 health survey questionnaire, were measured. Participants Over 3000 South Australian adults were interviewed in their own home by trained health interviewers in each of the surveys; in the 2008 survey, 1555 women participated, of whom 953 were over age 40.
After a peak in use in the 2000 survey, HT use fell from 2003 and has continued to decline in 2008. In 2008, current use over age 50 of registered conventional HT products is now 11.8%, with a further 4.0% using non-registered alternative 'hormonal' products. Current HT use is highest between the ages of 50 and 59 years, where 13.4% use conventional HT and 7.7% use unconventional alternative hormones. Use of these unregistered hormonal products was rare in previous surveys. Median and mean length of conventional HT use were 10.0 and 10.5 years, respectively. HT users continued to have a demographic profile similar to those in previous surveys, i.e. they were better educated, employed, partnered, had a higher income and were less inclined to use complementary and alternative medicines.
There has been a continuing decline in both the overall prevalence and length of use of conventional HT from 2003, probably in association with negative media about HT. Of medical concern is that about one-quarter of women using HT around menopause now chooses unregistered hormonal mixtures that are untested for long-term safety and efficacy.
描述2008年澳大利亚人群中绝经激素治疗（HT）的流行情况以及过去17年的趋势。
数据来自1991年至2008年对南澳大利亚人群进行的九次具有代表性的面对面人口访谈调查。这些调查采用了一致的方法和质量控制程序。2008年，使用SF-36健康调查问卷测量了人口统计学数据、HT使用情况以及八个健康维度。参与者 在每次调查中，超过3000名南澳大利亚成年人在自己家中接受了经过培训的健康访谈员的访谈；在2008年的调查中，1555名女性参与，其中953名年龄超过40岁。
在2000年调查中HT使用达到峰值后，从2003年开始下降，并在2008年持续下降。2008年，50岁以上人群中目前使用注册常规HT产品的比例为11.8%，另有4.0%使用未注册的替代“激素”产品。目前HT使用在50至59岁年龄段最高，其中13.4%使用常规HT，7.7%使用非常规替代激素。在之前的调查中很少使用这些未注册的激素产品。常规HT使用的中位数和平均时长分别为10.0年和10.5年。HT使用者的人口统计学特征与之前调查中的人群相似，即他们受教育程度更高、有工作、已婚、收入更高且不太倾向于使用补充和替代药物。
自2003年以来，常规HT的总体流行率和使用时长持续下降，这可能与关于HT的负面媒体报道有关。医学上关注的是，现在约四分之一在绝经前后使用HT的女性选择了未注册的激素混合物，这些产品未经过长期安全性和有效性测试。
